The Russian Ministry of Health has approved a number of local bioequivalence clinical studies the ARS CRO clinical operations team is going to initiate next month.  One will be the study of generic Sildenafil and sponsored by the leading Russian pharmaceutical company. A set of other clinical research projects (Montelukast, Gefitinib, Carbocisteine, Entecavir, Ritonavir, and FDC of Emtricitabine + Efavirenz + Tenofovir) will be performed for two leading Indian pharmaceutical companies. Full-service support will be provided by ARS.